Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

Boston Scientific Corp Profile



Ticker SymbolBSX

Company nameBoston Scientific Corp

IPO dateMay 19, 1992

CEOMahoney (Michael F)

Number of employees53000

Security typeOrdinary Share

Fiscal year-endMay 19

Address300 Boston Scientific Way

CityMARLBOROUGH

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited States of America

Postal code01752-1234

Phone15086834000

Websitehttps://www.bostonscientific.com/en-US/Home.html

Ticker SymbolBSX

IPO dateMay 19, 1992

CEOMahoney (Michael F)

Company Executives of Boston Scientific Corp



Name

Name/Position

Position

Shareholding

Change

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

2.05M

+9.09%

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

2.05M

+9.09%

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

2.05M

+9.09%

Mr. John E. Sununu

Independent Director

54.72K

Mr. Vance R. Brown

Executive Vice President, General Counsel, Corporate Secretary

54.24K

Mr. Vance R. Brown

Executive Vice President, General Counsel, Corporate Secretary

54.24K

Mr. Vance R. Brown

Executive Vice President, General Counsel, Corporate Secretary

54.24K

Mr. Jonathan R. Monson

Chief Financial Officer, Executive Vice President

39.06K

+2.76%

Mr. Jonathan R. Monson

Chief Financial Officer, Executive Vice President

39.06K

+2.76%

Mr. Jonathan R. Monson

Chief Financial Officer, Executive Vice President

39.06K

+2.76%

Name

Name/Position

Position

Shareholding

Change

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

2.05M

+9.09%

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

2.05M

+9.09%

Mr. Michael F. (Mike) Mahoney

Chairman of the Board, President, Chief Executive Officer

2.05M

+9.09%

Mr. John E. Sununu

Independent Director

54.72K

Mr. Vance R. Brown

Executive Vice President, General Counsel, Corporate Secretary

54.24K

Mr. Vance R. Brown

Executive Vice President, General Counsel, Corporate Secretary

54.24K

FAQs

Who are the top five shareholders of Boston Scientific Corp?



The top five shareholders of Boston Scientific Corp are: Mr. Michael F. (Mike) Mahoney

How many institutions hold shares of Boston Scientific Corp (BSX)?



As of 2026Q1, 3113 institutions hold shares of Boston Scientific Corp, with a combined market value of approximately 1.40B, accounting for 94.35% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -15512534.00.

What is the biggest source of revenue for Boston Scientific Corp?



In 2026Q1, the Interventional Cardiology Therapies business generated the highest revenue for Boston Scientific Corp, amounting to 1.33B and accounting for 24.49% of total revenue.